The benefit with respect to CKD progression was lower than that reported with Canagliflozin in the CREDENCE trial, more likely because SGLT2-i were allowed in the FIDELIO-DKD, thus leading to a higher renoprotection in the placebo group, whereas patients treated with mineralocorticoid receptor antagonists were excluded from the CREDENCE trial [78]. This evidence concerns the gene SLC5A2 and chronic kidney disease.